National Cancer Institute
- Address
- Via Giacomo Venezian 1, 20133 Milan, Italy
Neoplasms
The National Cancer Institute in Milan is conducting a study that evaluates olaparib together with bevacizumab as maintenance treatment for patients with advanced high‑grade epithelial ovarian, fallopian tube or primary peritoneal cancer. The trial focuses on individuals whose tumors are identified as HRD‑positive, aiming to improve long‑term outcomes after standard platinum‑based chemotherapy. It evaluates the combination of olaparib and bevacizumab as a maintenance strategy.
- First‑line maintenance therapy with a PARP inhibitor
- Integration of anti‑angiogenic therapy
- Use of HRD genomic testing to select patients
The research team includes 32 investigators and reflects the site’s commitment to innovative cancer therapies.
Digestive System Diseases
The National Cancer Institute is investigating the efficacy of bezuclastinib combined with sunitinib compared with sunitinib alone in subjects diagnosed with gastrointestinal stromal tumor. The study evaluates the potential benefit of adding bezuclastinib to standard therapy to improve disease control while monitoring safety.
- Comparison of combination versus monotherapy
- Targeted treatment for GIST
- Assessment of progression‑free survival
The trial benefits from the expertise of 32 investigators and supports the site’s focus on advancing therapies for digestive system cancers.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in National Cancer Institute
lock Showing 1 of 3 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (Peak) A Phase 3 Randomized, Open-label, Multicenter Clinical Study of CGT9486+Sunitinib vs Sunitinib in Subjects with Locally Advanced, Unresectable, or Metastatic Gastrointestinal Stromal Tumors | Cogent Biosciences Inc. | Phase III | Not Recruiting | Mar 2023 | — |
IMP list
lock Showing 1 of 9 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Carboplatin | 2 | Unknown | 2023-06-16 | 2023-10-03 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.